UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 4, 2020
JAGUAR HEALTH, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-36714
|
|
46-2956775
|
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
200 Pine Street, Suite 400
San Francisco, California
|
|
94104
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (415) 371-8300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, Par Value $0.0001 Per Share
|
|
JAGX
|
|
The Nasdaq Capital Market
|
Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On December 4, 2020, Jaguar Health, Inc. (the “Company”) filed a corrected certificate of amendment (the “Corrected Certificate of Amendment”) to the Company’s Third Amended and Restated Certificate of Incorporation (the “COI”) to correct certain clerical errors in the Company’s Fourth Amendment to the COI (the “Fourth Amendment”), including incorrect references therein to the Fourth Amendment as the “Fifth Amendment,” previously filed on June 3, 2019 with the Secretary of State of the State of Delaware Secretary of State.
The foregoing description of the Corrected Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Corrected Certificate of Amendment, which is filed as Exhibit 3.1 to this report and is incorporated by reference herein.
Item 5.07 Submission of Matters to a Vote of Security Holders.
At a special meeting of stockholders of the Company held on December 9, 2020 (“Special Meeting”), the following proposal was brought before the meeting: a proposal to grant discretionary authority to adjourn the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposal 1 (as defined below) (“Proposal 2”).
The final results with respect to Proposal 2 are set forth below.
Proposal 2 — Proposal to grant discretionary authority to adjourn the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposal 1 was approved by the stockholders by the following vote:
|
For
|
|
Against
|
|
Abstained
|
|
Broker Non-
Votes
|
|
|
32,724,785
|
|
11,988,265
|
|
706,202
|
|
0
|
|
Since there were insufficient votes at the time of the Special Meeting to approve the proposal to approve the adoption of an amendment to the COI to effect a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share (the “Common Stock”) at a ratio not less than 1-for-2 and not greater than 1-for-20, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before December 9, 2021 (the “Reverse Stock Split”) without further approval or authorization of the Company’s stockholders (“Proposal 1”), in accordance with the authority granted pursuant to the approval of Proposal 2, the Special Meeting was adjourned to 8:30 a.m., Pacific Time, on Tuesday, December 22, 2020. The Company’s stockholders of record as of the close of business on November 6, 2020 will continue to be entitled to vote at the special meeting on December 22, 2020. The reconvened special meeting will be held at the Company’s offices at 200 Pine Street, Suite 400, San Francisco, CA 94104.
As disclosed in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on November 6, 2020 (the “Proxy Statement”), the Company is seeking stockholder approval to effect the Reverse Stock Split primarily to increase the price of the Company’s common stock in order to meet the minimum bid price requirement for continued listing on The Nasdaq Stock Market. With respect to the bid price requirement, as previously disclosed, the Company received an unsolicited letter (the “Letter”) on December 2, 2020 from the Office of Appeals and Review of The Nasdaq Stock Market LLC (“Nasdaq”) staying the stipulation for the Company to comply with the minimum bid price requirement by December 23, 2020 set forth in the October 28, 2020 decision of the Nasdaq Listing Qualifications Panel (the “Panel”) pending the review of the Panel’s decision by the Nasdaq Listing and Hearing Review Council (the “Listing Council”). The Listing Council stated that it will consider whether the Panel should have granted the Company a longer period to regain compliance with the bid price requirement.
Item 7.01 Regulation FD Disclosure.
On December 4, 2020, the Company issued a press release announcing an amendment to the previously disclosed accounts receivable purchase agreement, dated May 12, 2020, by and among the Company, Napo Pharmaceuticals, Inc. (“Napo”), a wholly-owned subsidiary of the Company, and Oasis Capital, LLC (the “Agreement”), pursuant to which, among other things, the parties agreed to the sale of additional accounts receivable under the Agreement. A copy of the press release is furnished as Exhibit 99.1.
On December 10, 2020, the Company issued a press release announcing that it adjourned the Special Meeting to December 22, 2020 at 8:30 a.m. Pacific Time / 11:30 a.m. Eastern Time and will conduct an investor call on Thursday, December 17 at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to allow the Company’s management to review developments that have taken place since the Proxy Statement was filed. A copy of the press release is furnished as Exhibit 99.2 to this report.
The information in Item 7.01 of this Form 8-K and Exhibits 99.1 and 99.2 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
2
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
JAGUAR HEALTH, INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Lisa A. Conte
|
|
|
|
Name:
|
Lisa A. Conte
|
|
|
|
Title:
|
Chief Executive Officer & President
|
|
|
|
|
|
|
Date: December 10, 2020
|
|
|
|
4
Exhibit 3.1
CORRECTED
CERTIFICATE OF AMENDMENT
OF
JAGUAR HEALTH, INC.
Jaguar Health, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows:
1. The name of the Corporation is: Jaguar Health, Inc.
2. That a Certificate of Fifth Amendment to the Third Amended and Restated Certificate of Incorporation was filed with the Secretary of State of Delaware on June 3, 2019, with an effective date of June 7, 2019 (the “Certificate”), and that said Certificate requires correction as permitted by Section 103(f) of the Delaware General Corporation Law of the State of Delaware.
3. The inaccuracy or defect of said Certificate to be corrected is as follows:
(i) The title of the Certificate should refer to the “Certificate of Fourth Amendment to the Third Amended and Restated Certificate of Incorporation”, not the “Certificate of Fifth Amendment to the Third Amended and Restated Certificate of Incorporation.”
(ii) The first sentence of Paragraph 2 of the Certificate should refer to the “Certificate of Fourth Amendment to the Third Amended and Restated Certificate of Incorporation”, not the “Certificate of Fifth Amendment to the Third Amended and Restated Certificate of Incorporation.”
(iii) Paragraph 4 of the Certificate should refer to the “Certificate of Fourth Amendment to the Third Amended and Restated Certificate of Incorporation,” not the “Certificate of Fifth Amendment to the Third Amended and Restated Certificate of Incorporation.”
(iv) The last paragraph of the Certificate should refer to the “Certificate of Fourth Amendment to the Third Amended and Restated Certificate of Incorporation,” not the “Certificate of Fifth Amendment to the Third Amended and Restated Certificate of Incorporation.”
(v) The date in the last paragraph of the Certificate should be the 3rd day of June, 2019.
4. The Certificate is attached in its corrected form as Exhibit A.
1
IN WITNESS WHEREOF the said Corporation has caused this certificate to be signed this 3rd day of December, 2020.
|
|
By:
|
/s/ Lisa A. Conte
|
|
|
Name:
|
Lisa A. Conte
|
|
|
Title:
|
Chief Executive Officer
|
2
Exhibit A
CERTIFICATE OF FOURTH AMENDMENT TO THE
THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF
JAGUAR HEALTH, INC.
Jaguar Health, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies that:
1. The name of the Corporation is Jaguar Health, Inc. The date of filing of the Corporation’s original Certificate of Incorporation with the Secretary of State of the State of Delaware was June 6, 2013, under the name Jaguar Animal Health, Inc.
2. This Certificate of Fourth Amendment to the Third Amended and Restated Certificate of Incorporation was duly authorized and adopted by the Corporation’s Board of Directors and stockholders in accordance with Section 242 of the General Corporation Law of the State of Delaware and amends the provisions of the Company’s Third Amended and Restated Certificate of Incorporation.
3. The amendment to the existing Third Amended and Restated Certificate of Incorporation being effected hereby is as follows:
a. Add the following paragraph at the end of Section IV.A. as a new Section IV.A.7:
“7. Second Reverse Stock Split. Upon this Amendment to the Third Restated Certificate becoming effective pursuant to the DGCL (the “Effective Time”), each thirty to seventy shares of Common Stock issued and outstanding immediately prior to the Effective Time shall automatically be reclassified and combined into one (1) validly issued, fully paid and non-assessable share of Common Stock, the exact ratio within the foregoing range to be determined by the Board of Directors prior to the Effective Time and publicly announced by the Corporation, without any further action by the Corporation or the holder thereof (the “Second Reverse Stock Split”). No fractional shares shall be issued in connection with the Second Reverse Stock Split. Stockholders who otherwise would be entitled to receive fractional shares of Common Stock shall be entitled to receive cash (without interest or deduction) from the Corporation’s transfer agent in lieu of such fractional share interests upon the submission of a transmission letter by a stockholder holding the shares in book-entry form and, where shares are held in certificated form, upon the surrender of
3
the stockholder’s Old Certificates (as defined below), in an amount equal to the product obtained by multiplying (a) the closing price per share of the Common Stock as reported on the Nasdaq Capital Market as of the date of the Effective Time, by (b) the fraction of one share owned by the stockholder. Each certificate that immediately prior to the Effective Time represented shares of Common Stock (“Old Certificates”), shall thereafter represent that number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above.”
4. This Certificate of Fourth Amendment to the Third Amended and Restated Certificate of Incorporation shall be effective at 12:01 a.m., Eastern Time, on June 7, 2019.
IN WITNESS WHEREOF, Jaguar Health, Inc. has caused this Certificate of Fourth Amendment to the Third Amended and Restated Certificate of Incorporation to be signed by Lisa A. Conte, its Chief Executive Officer, this 3rd day of June, 2019.
|
|
JAGUAR HEALTH, INC.
|
|
|
|
|
|
A Delaware corporation
|
|
|
|
|
|
|
By:
|
/s/ Lisa A. Conte
|
|
|
|
Name:
|
Lisa A. Conte
|
|
|
|
Title:
|
Chief Executive Officer
|
4
Exhibit 99.1
Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Fifth Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020
The Sixth Tranche Accounts Receivable has a gross value of $3,810,587.04, representing customer billings over a 51-day period
SAN FRANCISCO, CA / December 4, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, Inc., (collectively, the “Company”) have jointly entered into a fifth amendment to the accounts receivable purchase agreement with Oasis Capital, LLC (“Oasis”), dated May 12, 2020, pursuant to which Oasis agreed to purchase additional accounts receivable of the Company related to the sales of the Company’s Mytesi® drug product to Cardinal Health for the period of October 13, 2020 through December 2, 2020 (the “Sixth Tranche Accounts Receivable”). The Sixth Tranche Accounts Receivable has a gross value of $3,810,587.04, representing customer billings over a 51-day period.
“We are happy to enter into this additional amendment with Oasis. Based on the success of the previous five tranches of accounts receivable financing and the strength of our growing sales of Mytesi, we have been able to further our strategy of bringing in non-dilutive capital and striving to become a sustainable, cash flow positive commercial business,” said Lisa Conte, Jaguar’s president and CEO.
Per the terms of the agreement, Oasis will receive a fee of 5.45% (the “Fee”) of the $3,810,587.04 Sixth Tranche Accounts Receivable following their purchase of the Sixth Tranche Accounts Receivable for $1,619,499.49, an increased percentage of the gross accounts receivable compared to the April 2020 purchase (the “Purchase Price”). As with prior accounts receivable sales to Oasis, Oasis will return to the Company any amount that exceeds the sum of the Purchase Price and the Fee. As with all Mytesi gross sales, the Sixth Tranche Accounts Receivable will be reduced by Medicare, ADAP 340B chargebacks, returns, and wholesale distribution fees based on historical trends to determine net sales.
Under the amendment, Oasis is entitled to a one-time transaction fee of $5,000.
About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.
About Mytesi®
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements.” In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
Exhibit 99.2
Jaguar Health Announces Adjournment of Its Special Meeting of Stockholders Until Tuesday, December 22, 2020
Jaguar to Host Investor Call Thursday, December 17th at 8:30 a.m. Eastern to Allow Management to Review Developments that Have Taken Place Since the Definitive Proxy Statement was Filed
As previously announced, Nasdaq’s Listing and Hearing Review Council Stayed the Panel Determination Requiring Jaguar’s Compliance with the Bid Price Requirement by December 23, 2020
San Francisco, CA (December 10, 2020): Jaguar Health, Inc. (Nasdaq: JAGX) (“Jaguar” or the “Company”) today announced that its Special Meeting of Stockholders held on December 9, 2020 (the “Special Meeting”) was adjourned to allow the Company additional time to solicit proxies.
Jaguar is hosting an investor call on Thursday, December 17th at 8:30 a.m. Eastern Standard Time to allow management to review developments that have taken place since the Proxy Statement was filed. Dial-in instructions for the call appear below.
The Special Meeting has been adjourned to 8:30 a.m. Pacific Standard Time/11:30 a.m. Eastern Standard Time on Tuesday, December 22, 2020, at the offices of the Company at 200 Pine Street, Suite 400, San Francisco, CA 94104.
“We adjourned our Special Meeting to solicit additional proxies to provide the option for Jaguar’s Board of Directors to be able to take the actions, if necessary, at some future date, to maintain the Company’s listing on The Nasdaq Capital Market (“Nasdaq”). Jaguar’s Board and management are optimistic about the future, and seeking the discretion to implement actions, if necessary to maintain Jaguar’s Nasdaq listing, is an important responsibility of the Board. At this time, with the stay provided by Nasdaq’s Listing and Hearing Review Council (the “Listing Council”), there is no intention or rationale to implement any actions by the Board. The shareholder vote is important because we’re seeking to provide that discretion to the Board for the future,” commented Lisa Conte.
“As we announced earlier this week, the Listing Council stayed the October 28, 2020 decision of the Nasdaq Listing Qualifications Panel (the “Panel”) requiring Jaguar’s compliance with the Bid Price Requirement by December 23, 2020. We were very happy to learn that the Listing Council, of its own accord, exercised its discretion to review the Panel’s decision. We believe our efforts since the second quarter of 2020 to implement our expanded patient access programs for Mytesi® (crofelemer) and our focus on long-term investors and non-dilutive financings, including our recent royalty-based capital infusion of $6.0 million, are improving our long-term financial prospects. Additionally, with the initiation this past October by our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., of the pivotal Phase 3 clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy (“cancer therapy-related diarrhea” (CTD)), and our recently announced plans to develop and commercialize crofelemer for the possible indication of prophylaxis and/or symptomatic relief of inflammatory diarrhea — initially to be studied in a ‘long-hauler’ COVID-19 recovery patient population in Europe — we believe the value generated in the Company will be realized as we work to regain compliance with the Nasdaq bid price requirement.”
The Company is engaged in preliminary discussions with Swiss Growth Forum, a sponsor of a European special purpose acquisition company, “Post Pandemic Recovery Equity” (“the SPAC”), regarding the SPAC’s potential merger with an operational subsidiary of the Company to be established in Europe with an exclusive license to crofelemer and Mytesi for the indications of inflammatory diarrhea and HIV-related diarrhea. Jaguar management looks forward to providing updates during the investor call on Thursday, December 17th regarding the progress of the European road show related to this potential merger.
Dial-In Instructions for Investor Call
When: Thursday, December 17, 2020 at 8:30 a.m. Eastern Time
Dial-in (US Toll Free): 888-394-8218
Dial-in (International): 323-701-0225
Conference ID number: 3973780
Live webcast on the investor relations section of Jaguar’s website (click here)
Replay Instructions for Investor Call
Dial-in (US Toll Free): 844-512-2921
Dial-in (International): 412-317-6671
Replay Pin Number: 3973780
Replay of the webcast on the investor relations section of Jaguar’s website (click here)
About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.
About Mytesi®
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the Company’s plan to host an investor call on Thursday, December 17, 2020, the Company’s belief that its efforts since the second quarter of 2020 to implement its expanded patient access programs for Mytesi, and the Company’s focus on long-term investors and non-dilutive financings, including its recent royalty-based capital infusion, are improving Jaguar’s long-term financial prospects, the belief that, with the initiation by Napo of the pivotal Phase 3 clinical trial of crofelemer CTD, and the Company’s recently announced plans to develop and commercialize crofelemer for the possible indication of prophylaxis and/or symptomatic relief of inflammatory diarrhea — initially to be studied in a ‘long-hauler’ COVID-19 recovery patient population in Europe — the value generated in the Company will be realized as the Company works to regain compliance with the Nasdaq bid price requirement, and the SPAC’s potential merger with an operational subsidiary of the Company to be established in Europe with an exclusive license to crofelemer and Mytesi for the indications of inflammatory diarrhea and HIV-related diarrhea. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX